Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, today announced a licensing agreement with Zymeworks Inc. (Zymeworks) (NYSE: ZYME) to utilize their ZymeLink™ technology to develop novel antibody-drug conjugates (ADCs) and declared ATRC-301, an ADC targeting a novel epitope on EphA2, as the Company’s next clinical candidate. Atreca management will discuss the agreement, ATRC-301, and its earlier stage pipeline programs during today’s R&D Day beginning at 4:15pm EDT.
R&D Day Webcast and Conference Call Details
The live R&D Day webcast, including accompanying slides, can be accessed through the Events & Presentations section of the Company's website at https://ir.atreca.com/news-and-events/event-calendar. To access the event by telephone, please dial (800) 373-6606 (United States) or (409) 937-8918 (international) and reference the conference ID 3490903. An archived replay of the webcast will be available on the Company's website following the live event.
https://finance.yahoo.com/news/atreca-announces-expansion-preclinical-pipeline-200100167.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.